SENSITIVE MEMORY TESTS FOR DIFFERENTIATING MCI SUBGROUPS

用于区分 MCI 子组的灵敏内存测试

基本信息

批准号：
7618208
负责人：
Stuart Zola
金额：
$ 24.72万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7618208
关键词：
Alzheimer&apos s Disease Amnesia Animal Model Area Autopsy Behavior Behavioral Brain Brain imaging Brain scan Categories Chromosomes, Human, Pair 1 Classification Clinical Cognitive Control Groups Corpus striatum structure Databases Dementia Development Devices Diagnosis Diagnostic Dissociation Early Diagnosis Event Eye Genetic Genetic Predisposition to Disease Goals Habits Human Imaging technology Impaired cognition Individual Intervention Lead Life Link Lobe Magnetic Resonance Imaging Measures Medial Mediating Memory Memory Loss Memory impairment Methods Motor Skills Nervous system structure Neurologic Neurosciences Numbers Other Finding Parkinson Disease Patients Pattern Performance Population Prevention Recruitment Activity Research Design Research Personnel Risk Role Scanning Structure Symptoms System Technology Temporal Lobe Testing Therapeutic Intervention Time Work base behavior test experience follow-up implicit memory innovation memory process memory recognition mild neurocognitive impairment neuropathology patient registry programs relating to nervous system research and development tool

项目摘要

The diagnostic category of amnesia associated with mild cognitive impairment (MCI) attempts to describe those people who have memory loss but relatively preserved abilities in other cognitive areas so as not to merit a diagnosis of dementia. The importance of this group of people is that they represent a population at high risk of developing dementia, especially Alzheimer's disease, and are an appropriate target for early diagnosis and intervention strategies. Accordingly, the major goal of this proposal is to determine whether sensitive behavioral tasks together with eye-tracking technology will reveal a profile of performance in MCI patients that is useful in predicting the onset of Alzheimer's Disease or other dementias. The overall plan is to test a minimum of 60 MCI patients and 60 matched normal control (NC) subjects (recruited from the Clinical Core) initially and on yearly follow-up sessions on two declarative memory tasks and one nondeclarative memory task, together with eye-tracking. We have good experience with all of the tasks and with eye-tracking, and we have successfully administered the preferential looking task together with eye-tracking in pilot work with MCI, PD, and NC subjects. A group of 30 patients with Alzheimer's Disease (AD) and a group of 30 Parkinson's Disease patients without dementia (PD) also will be tested (these groups will also be recruited from the Clinical Core). The performance of the AD and PD groups and the NC group will provide important points of comparison with the performance of the MCI patients initially and at follow-up sessions. The PD group also serves as a critical control group for the MCI and AD patients. Specifically, PD patients, like the AD patients, have neurologic damage, but unlike AD patients, the PD patients don't have dementia. An important contribution from this work would be the ability to diagnose sooner than is now possible in MCI patients oncoming cognitive decline, at a time when the nervous system is less compromised and, accordingly, more likely to benefit from therapeutic intervention.

与轻度认知障碍（MCI）相关的健忘症的诊断类别试图描述那些在其他认知领域相对保留但相对保留的能力的人，以便不值得诊断痴呆症。这组人的重要性是，他们代表了患痴呆症的高风险，尤其是阿尔茨海默氏病的人群，并且是早期诊断和干预策略的适当目标。因此，该提案的主要目的是确定敏感的行为任务以及眼睛跟踪技术是否会揭示MCI患者的表现概况，这在预测阿尔茨海默氏病或其他痴呆症的发作中有用。总体计划是至少测试60名MCI患者和60名匹配的正常对照（NC）受试者（从该受试者中招募临床核心）最初，并在两项声明性记忆任务和一项非确切记忆任务的年度后续课程中，以及令人眼前一亮的记忆任务。我们在所有任务和眼神招标方面都有良好的经验，并且我们已经成功地管理了优先外观的任务，并与MCI，PD和NC受试者进行了试验。一组30例阿尔茨海默氏病（AD）和30例无痴呆症患者（PD）的患者也将进行测试（这些组也将从临床核心招募）。 AD和PD组的性能以及NC组将与MCI患者的性能最初和随访时提供重要的比较点。 PD组也是MCI和AD患者的关键对照组。具体而言，PD 像AD患者一样，患者患有神经系统损害，但与AD患者不同，PD患者没有痴呆症。这项工作的一个重要贡献是，在神经系统受到损害较低的时候，并且更有可能受益于治疗干预措施，迎接认知能力下降的MCI患者的诊断能力要早。